Ozempic side effects: every rate on the FDA label
The most common adverse reactions reported in ≥5% of patients treated with OZEMPIC are: nausea, vomiting, diarrhea, abdominal pain and constipation. (6.1) dailymed.nlm.nih.gov, Sep 27, 2026
Ozempic is labeled for type 2 diabetes; these rates come from diabetes trials.
Ozempic injection
Boxed warning
WARNING: RISK OF THYROID C-CELL TUMORS
dailymed.nlm.nih.gov, Sep 27, 2026In rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures.
dailymed.nlm.nih.gov, Sep 27, 2026
| Side effect | Placebo | 0.5 mg | 1 mg |
|---|---|---|---|
| Nausea | 6.1% | 15.8% | 20.3% |
| Vomiting | 2.3% | 5% | 9.2% |
| Diarrhea | 1.9% | 8.5% | 8.8% |
| Abdominal pain | 4.6% | 7.3% | 5.7% |
| Constipation | 1.5% | 5% | 3.1% |
Percent of people in the trial who reported it. Placebo is the comparison group.
- Dyspepsia and eructation (<5%, text): placebo; 0.5 mg; 1 mg.
In addition to the reactions in Table 1, the following gastrointestinal adverse reactions with a frequency of <5% were associated with OZEMPIC (frequencies listed, respectively, as: placebo; 0.5 mg; 1 mg): dyspepsia (1.9%, 3.5%, 2.7%), eructation (0%, 2.7%, 1.1%), flatulence (0.8%, 0.4%, 1.5%), gastroesophageal reflux disease (0%, 1.9%, 1.5%), and gastritis (0.8%, 0.8%, 0.4%).
dailymed.nlm.nih.gov, Sep 27, 2026 - Injection site reactions 0.2%.
In placebo-controlled trials, injection site reactions (e.g., injection-site discomfort, erythema) were reported in 0.2% of OZEMPIC-treated patients.
dailymed.nlm.nih.gov, Sep 27, 2026 - Fatigue and dizziness: >0.4% (no exact rate).
Other adverse reactions with a frequency of >0.4% were associated with OZEMPIC include fatigue, dysgeusia and dizziness.
dailymed.nlm.nih.gov, Sep 27, 2026
Who stopped because of side effects
- GI-related discontinuation only: 3.1% (0.5 mg), 3.8% (1 mg) vs 0.4% placebo.
More patients receiving OZEMPIC 0.5 mg (3.1%) and OZEMPIC 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.4%).
dailymed.nlm.nih.gov, Sep 27, 2026
Who should not take it, pregnancy and breastfeeding
- Contraindicated with personal/family history of MTC or MEN 2.
A personal or family history of MTC or in patients with MEN 2 [see Warnings and Precautions (5.1)].
dailymed.nlm.nih.gov, Sep 27, 2026 - Contraindicated after serious hypersensitivity to semaglutide or excipients.
A serious hypersensitivity reaction to semaglutide or to any of the excipients in OZEMPIC. Serious hypersensitivity reactions including anaphylaxis and angioedema have been reported with OZEMPIC [see Warnings and Precautions (5.8)].
dailymed.nlm.nih.gov, Sep 27, 2026 - Use in pregnancy only if benefit justifies risk.
OZEMPIC should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
dailymed.nlm.nih.gov, Sep 27, 2026 - Stop at least 2 months before a planned pregnancy.
Females and Males of Reproductive Potential: Discontinue OZEMPIC in women at least 2 months before a planned pregnancy due to the long washout period for semaglutide. (8.3)
dailymed.nlm.nih.gov, Sep 27, 2026 - No human milk data.
There are no data on the presence of semaglutide in human milk, the effects on the breastfed infant, or the effects on milk production.
dailymed.nlm.nih.gov, Sep 27, 2026
Label revised 5/2026: read the full label on DailyMed. The label lists more reactions and warnings than this page.
Ozempic tablets
Boxed warning
WARNING: RISK OF THYROID C-CELL TUMORS
dailymed.nlm.nih.gov, Sep 27, 2026In rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures.
dailymed.nlm.nih.gov, Sep 27, 2026
| Side effect | Placebo | 7 mg | 14 mg |
|---|---|---|---|
| Nausea | 6% | 11% | 20% |
| Abdominal Pain | 4% | 10% | 11% |
| Diarrhea | 4% | 9% | 10% |
| Vomiting | 3% | 6% | 8% |
| Constipation | 2% | 6% | 5% |
Percent of people in the trial who reported it. Placebo is the comparison group.
- Safety data come from RYBELSUS (semaglutide tablets 3/7/14 mg) studies.
The safety of OZEMPIC tablets (1.5 mg, 4 mg and 9 mg strengths) [see Dosage and Administration (2.2)] and RYBELSUS (3 mg, 7, mg and 14 mg strengths) [see Dosage and Administration (2.2)] has been established as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus based on adequate and well-controlled studies of RYBELSUS in adult patients with type 2 diabetes mellitus
dailymed.nlm.nih.gov, Sep 27, 2026 - Dyspepsia and eructation (<5%, text): 14 mg, 7 mg, placebo.
In addition to the reactions in Table 2, the following gastrointestinal adverse reactions with a frequency of <5% occurred in semaglutide tablets -treated patients (frequencies listed, respectively, as 14 mg once daily, 7 mg once daily and placebo): abdominal distension (3%, 2% and 1%), dyspepsia (0.6%, 3%, 0.6%), eructation (2%, 0.6%, 0%,), flatulence (1%, 2%, 0%), gastroesophageal reflux disease (2%, 2%, 0.3%) and gastritis (2%, 2%, 0.8%).
dailymed.nlm.nih.gov, Sep 27, 2026
Who stopped because of side effects
- CV outcomes trial: 15.5% vs 11.6% placebo stopped for an adverse event.
Study drug was permanently discontinued due to an adverse event in 15.5% of semaglutide tablets-treated patients and 11.6% of placebo-treated patients.
dailymed.nlm.nih.gov, Sep 27, 2026 - GI-related discontinuation: 8% (14 mg), 4% (7 mg) vs 1% placebo.
A greater percentage of patients who received semaglutide tablets 14 mg once daily (8%) and semaglutide tablets 7 mg once daily (4%) discontinued treatment due to gastrointestinal adverse reactions than patients who received placebo (1%).
dailymed.nlm.nih.gov, Sep 27, 2026
Who should not take it, pregnancy and breastfeeding
- Contraindicated with personal/family history of MTC or MEN 2.
A personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) [see Warnings and Precautions (5.1)].
dailymed.nlm.nih.gov, Sep 27, 2026 - Contraindicated after serious hypersensitivity to semaglutide or excipients.
A prior serious hypersensitivity reaction to semaglutide or to any of the excipients in RYBELSUS or OZEMPIC tablets. Serious hypersensitivity reactions including anaphylaxis and angioedema have been reported with semaglutide tablets [see Warnings and Precautions (5.7)].
dailymed.nlm.nih.gov, Sep 27, 2026 - Use in pregnancy only if benefit justifies risk.
RYBELSUS or OZEMPIC tablets should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
dailymed.nlm.nih.gov, Sep 27, 2026 - Breastfeeding not recommended (SNAC).
Because of the unknown potential for serious adverse reactions in the breastfed infant due to the possible accumulation of SNAC, and because there are alternative semaglutide products that do not contain SNAC that can be used during lactation, advise patients that breastfeeding is not recommended during treatment with RYBELSUS or OZEMPIC tablets.
dailymed.nlm.nih.gov, Sep 27, 2026
Label revised 1/2026: read the full label on DailyMed. The label lists more reactions and warnings than this page.
Doses and schedule: Ozempic dosing · Price: Ozempic cost · All medications: side effects compared
This page reports what the label says; it is not medical advice. Tell your prescriber about any side effect.Medical disclaimer.